This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Migraine Milestones: When Translational Research Transforms Patient Care

Migraine Milestones: When Translational Research Transforms Patient Care



Time to Complete

1 hour


July 12, 2019


July 12, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM
1.00 / ABIM MOC Part II Point

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.

Commercial Supporter

This activity is supported by an independent educational grant provided by Teva.

Program Description

The field of migraine is undergoing a profound transformation. The pivotal scientific advances that have brought new, migraine-specific, selectively-targeted and therefore well-tolerated compounds from translational research through clinical research to clinical application provide new hope and significantly advanced therapeutic options for the almost 40 million migraine sufferers in the United States.

Intended Audience

This activity is intended for neurologists and primary care physicians engaged in the care of patients with migraines.

Educational Objectives

After completing this activity, participants should be better able to:

  • Identify gaps in the quality of care provided to patients with migraine, the impact on patient quality of life, and opportunities to improve outcomes
  • Summarize the efficacy, adverse effects and adherence challenges of older or non-specifically-targeted migraine therapies
  • Using efficacy and tolerability data from clinical trials, choose new migraine-specific, selectively-targeted therapies for migraine prevention and treatment for appropriate patients

Conflicts of Interest Disclosure Policy

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Stewart J. Tepper, MD (Program Chair)
Professor of Neurology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire
Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Dr. Tepper discloses the following:
Salary: American Headache Society, Dartmouth-Hitchcock Medical Center
Consulting fees: Acorda, Alder, Allergan, Amgen, Alexza, AlphaSights, Axsome, BioDelivery Sciences Int’l, Biohaven, Charleston Labs, Decision Resources, DeepBench, Dr Reddy’s, ElectroCore, Eli Lilly, eNeura, Expert Connect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion NeuroStim, Slingshot Insights, Sorrento, Sudler & Hennessey, Teva Pharmaceutical Industries Ltd, Theranica, Thought Leader Select, Trinity Partners, Xoc Pharmaceuticals, Zosano
Contracted research (no personal compensation): Alder, Allergan, Amgen, ATI, Dr Reddy’s[K
Contracted research: Electrocore, Neurolief, Scion, Teva Pharmaceutical Industries Ltd, Zosano
Ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): ATI

Merle L. Diamond, MD
Clinical Assistant Professor
Department of Medicine
Rosalind Franklin University of Medicine and Science/Chicago Medical School
President and Managing Director
Diamond Headache Clinic
Chicago, Illinois

Dr. Diamond discloses the following.
Consulting fees: Alder BioPharmacuticals, Amgen, Avanir Pharmaceuticals, Assertio Therapeutics (Formally known as Depomed), Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Upsher-Smith Laboratories
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agent: Amgen, Avanir, Assertio Therapeutics (Formally known as Depomed), Eli Lilly & Co, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd.

Planners and Managers

The PIM planners and managers have nothing to disclose.

The Miller Medical Communications, LLC, planners and managers have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Miller Medical Communications, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part II Points

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point [and patient safety MOC credit] in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.




There are no fees for participating and receiving CME/CE credit for this activity. During the period July 12, 2019 through July 12, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Contact Information for Questions About the Activity:
Kerri Leonard,, 212-661-7400, ext. 9

If you have any questions relating to the accreditation of this activity, please contact Postgraduate Institute for Medicine at: or (303) 799-1930.

Privacy Policy

Postgraduate Institute for Medicine Privacy Policy

Miller Medical Communications, LLC- Kerri Leonard,, 212-661-7400, ext. 9

myCME privacy policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue